--- title: "Chief Executive Officer Of BeOne Medicines Makes $501K Sale" type: "News" locale: "en" url: "https://longbridge.com/en/news/289939569.md" description: "BeOne Medicines CEO John Oyler sold 1,949 shares for $501,354, per an SEC Form 4 filing. The stock closed at $267.87, down 0.81%. BeOne is an oncology-focused biopharmaceutical company with strong revenue growth (35.46%) and high gross margins (88.95%), though EPS declined. Valuation metrics show a high P/E ratio but lower P/S compared to industry peers." datetime: "2026-06-16T15:02:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289939569.md) - [en](https://longbridge.com/en/news/289939569.md) - [zh-HK](https://longbridge.com/zh-HK/news/289939569.md) generator: "portal-rs" --- # Chief Executive Officer Of BeOne Medicines Makes $501K Sale On June 15, a recent SEC filing unveiled that **JOHN OYLER**, Chief Executive Officer at **BeOne Medicines** (NASDAQ:ONC) made an insider sell. **What Happened:** A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that OYLER sold 1,949 shares of **BeOne Medicines**. The total transaction amounted to $501,354. The latest market snapshot at Tuesday morning reveals **BeOne Medicines** shares down by 0.81%, trading at $267.87. ### All You Need to Know About BeOne Medicines BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products. ### Unraveling the Financial Story of BeOne Medicines **Positive Revenue Trend:** Examining BeOne Medicines's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of **35.46%** as of 31 March, 2026, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector. **Key Insights into Profitability Metrics:** - Gross Margin: The company excels with a remarkable gross margin of 88.95%, indicating superior cost efficiency and profitability compared to its industry peers. - Earnings per Share (EPS): BeOne Medicines's EPS reflects a decline, falling below the industry average with a current EPS of 2.08. **Debt Management:** With a below-average debt-to-equity ratio of **0.24**, BeOne Medicines adopts a prudent financial strategy, indicating a balanced approach to debt management. **Financial Valuation:** - Price to Earnings (P/E) Ratio: BeOne Medicines's current Price to Earnings (P/E) ratio of 60.68 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment. - Price to Sales (P/S) Ratio: The Price to Sales ratio is 5.36, which is lower than the industry average. This suggests a possible undervaluation based on sales performance. - EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): With an EV/EBITDA ratio of 28.3, the company's market valuation exceeds industry averages. **Market Capitalization:** With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers. ### Unmasking the Significance of Insider Transactions Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors. When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction. A new purchase by a company insider is a indication that they anticipate the stock will rise. On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors. ### A Closer Look at Important Transaction Codes Delving into transactions, investors typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A **P** in Box 3 indicates a purchase, while **S** signifies a sale. Transaction code **C** signals the conversion of an option, and transaction code **A** denotes a grant, award, or other acquisition of securities from the company. Check Out The Full List Of BeOne Medicines's Insider Trades. *This article was generated by Benzinga's automated content engine and reviewed by an editor.* ### Related Stocks - [ONC.US](https://longbridge.com/en/quote/ONC.US.md) - [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md) - [06160.HK](https://longbridge.com/en/quote/06160.HK.md) ## Related News & Research - [BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines | ONC Stock News](https://longbridge.com/en/news/297552849.md) - [BeOne Medicines Grants RSUs to 235 Employees Under Incentive Plan](https://longbridge.com/en/news/298025672.md) - [BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference | ONC Stock News](https://longbridge.com/en/news/297636674.md) - [CLSA: China Biotech Fundamentals Remain Solid; Top Picks BEONE MEDICINES , INNOVENT BIO and LEADS BIOLABS-B](https://longbridge.com/en/news/297994035.md) - [How Investors Are Reacting To BeOne Medicines (ONC) First-Line HER2-Positive GEA Immunotherapy Approval](https://longbridge.com/en/news/297146976.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**